[Treatment of psoriasis vulgaris with external sulfur mustard gas with particular reference to its potential carcinogenic risk. III. Clinical and experimental studies on the extent of percutaneous and inhalational uptake of sulfur mustard gas].
Concerning the often discussed carcinogenic risk of psoriasis treatment with 0.005% S-mustard-vaseline (so-called Russian Ointment) -- especially by inhalation -- 19 patients were treated with a radioactive labeled S-mustard-ointment and examined. The patients' whole bodies were inuncted for 1--2 days with about 50 g of radioactive S-mustard vaseline (U14C, 3 muCi/g). Afterwards the radioactivity was determined in the patients' expired air, blood, urine, and in their surrounding air. In three patients punch biopsy material from normal and psoriatic skin was assayed for radioactivity after combustion. In the skin, radioactivity distinctly decreased from the epidermis (13.1 pCi/mg) to the subcutis (0.77 pCi/mg) without significant differences between normal skin and psoriatic lesions as confirmed by autoradiography. In all samples of air, body fluids and tissue, definitive amounts of radioactivity were found, which, however, were far below the US-American MAK-values. Between skin surface and shirt, the values varied from 1.5 to 13.7 nCi/20 l air, at a distance of 2 meters by 0.3 nCi/100 l air, in the breath by 0.5 nCi/20 l. The radioactivity decreased to 1/10 of the maximum values after 1--2 hours. In blood the activity was at the limit of detection and was parallelled by the activity of the urine. Generally, 1--7% of the radioactivity applied to the skin was eliminated with the urine within one week. Thus, the carcinogenic risk may be very low in the external S-mustard therapy of psoriasis and other skin diseases.
D000388:Air / Q000032:analysis; D000818:Animals; D002250:Carbon Radioisotopes; D002273:Carcinogens; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004781:Environmental Exposure; D006801:Humans; D066298:In Vitro Techniques; D009150:Mustard Compounds / Q000627:therapeutic use*; D009151:Mustard Gas / Q000378:metabolism / Q000627:therapeutic use*; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D012306:Risk; D012869:Skin Absorption / Q000187:drug effects*; D013997:Time Factors; D014556:Urine / Q000032:analysis
D002250:Carbon Radioisotopes; D002273:Carcinogens; D009150:Mustard Compounds; D009824:Ointments; D009151:Mustard Gas
Die Behandlung der Psoriasis vulgaris mit Schwefel-Lost extern unter besonderer Berücksichtigung ihres möglichen Carcinogenese-Risikos. III. Mitteilung. Klinisch-experimentelle Untersuchungen über das Ausmass der percutanen und inhalativen Aufnahme von Schwefel-Lost.